Skip to main content
SpringerLink
Log in

NEUROMUSCULAR DISEASE

Treatment with cardiosphere-derived cells could slow progress of Duchenne muscular dystrophy

  • In Brief
  • Published:

From Nature Reviews Neurology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

Original article

  • McDonald, C. M. et al. Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 399, 1049–1058 (2022)

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Neurology http://www.nature.com/nrneurol/

    Sarah Lempriere

Authors
  1. Sarah Lempriere
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah Lempriere.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lempriere, S. Treatment with cardiosphere-derived cells could slow progress of Duchenne muscular dystrophy. Nat Rev Neurol 18, 251 (2022). https://doi.org/10.1038/s41582-022-00657-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-022-00657-2

  • Springer Nature Limited

Search

Navigation